Development of multidrug resistance (MDR) is a continuous clinical challenge partially due to the overexpression of P-glycoprotein (P-gp) for chronic myelogenous leukemia (CML) patients. This evidence concerns the gene PGP and chronic myelogenous leukemia, BCR-ABL1 positive.